INNA-051
INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory.[1][2]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intranasal |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
.svg.png.webp){kind=small} COVID-19 portal |
References
- "INNA-051 intranasal safety and tolerability study". anzctr.org.au. 21 April 2021. ACTRN12621000607875p. Retrieved 20 May 2021.
- Clinical trial number NCT05118763 for "Intranasal INNA-051 for Prevention of COVID-19 in Adults" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.